| Year |
Citation |
Score |
| 2016 |
Koso H, Yi H, Sheridan P, Miyano S, Ino Y, Todo T, Watanabe S. Identification of RNA-binding protein LARP4B as a tumor suppressor in glioma. Cancer Research. PMID 26933087 DOI: 10.1158/0008-5472.CAN-15-2308 |
0.309 |
|
| 2011 |
Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D, Ueki K, Ino Y, Todo T, Yamada Y, Fukayama M, Saito N, Miyazono K, Aburatani H. Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 12384-9. PMID 21750150 DOI: 10.1073/pnas.0906930108 |
0.492 |
|
| 2009 |
Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, Shibahara J, Louis DN, Reifenberger G, Itami J, Hara R, Saito N, Todo T. Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro-Oncology. 11: 446-51. PMID 19164434 DOI: 10.1215/15228517-2008-112 |
0.451 |
|
| 2001 |
Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. The American Journal of Pathology. 159: 359-67. PMID 11438483 DOI: 10.1016/S0002-9440(10)61702-6 |
0.719 |
|
| 2001 |
Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 839-45. PMID 11309331 |
0.691 |
|
| 2000 |
Tortosa A, Ino Y, Odell N, Swilley S, Sasaki H, Louis DN, Henson JW. Molecular genetics of radiographically defined de novo glioblastoma multiforme. Neuropathology and Applied Neurobiology. 26: 544-52. PMID 11123721 DOI: 10.1046/J.0305-1846.2000.00290.X |
0.666 |
|
| 2000 |
Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DN. Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics. 3: 45-6. PMID 11085597 DOI: 10.1007/PL00022979 |
0.466 |
|
| 2000 |
Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. International Journal of Radiation Oncology, Biology, Physics. 48: 825-30. PMID 11020580 DOI: 10.1016/S0360-3016(00)00703-3 |
0.665 |
|
| 2000 |
Misdraji J, Ino Y, Louis DN, Rosenberg AE, Chiocca EA, Harris NL. Primary lymphoma of peripheral nerve: report of four cases. The American Journal of Surgical Pathology. 24: 1257-65. PMID 10976700 DOI: 10.1097/00000478-200009000-00009 |
0.575 |
|
| 2000 |
Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, Ramsay DA, von Deimling A, Louis DN, Cairncross JG. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. Journal of Neurosurgery. 92: 983-90. PMID 10839259 DOI: 10.3171/Jns.2000.92.6.0983 |
0.746 |
|
| 2000 |
Møller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjødt K, Pedersen NT. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 14: 898-904. PMID 10803523 DOI: 10.1038/Sj.Leu.2401761 |
0.561 |
|
| 2000 |
Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Molecular and Cellular Biology. 20: 1436-47. PMID 10648628 DOI: 10.1128/Mcb.20.4.1436-1447.2000 |
0.493 |
|
| 1999 |
Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. The American Journal of Pathology. 155: 1879-84. PMID 10595918 DOI: 10.1016/S0002-9440(10)65507-1 |
0.668 |
|
| 1999 |
Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology. 117: 831-7. PMID 10500065 DOI: 10.1016/S0016-5085(99)70341-0 |
0.595 |
|
| 1999 |
Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, von Deimling A, Louis DN. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. Journal of Neuropathology and Experimental Neurology. 58: 881-5. PMID 10446812 DOI: 10.1097/00005072-199908000-00010 |
0.594 |
|
| 1999 |
Taylor MD, Perry J, Zlatescu MC, Stemmer-Rachamimov AO, Ang LC, Ino Y, Schwartz M, Becker LE, Louis DN, Cairncross JG. The hPMS2 exon 5 mutation and malignant glioma. Case report. Journal of Neurosurgery. 90: 946-50. PMID 10223463 DOI: 10.3171/jns.1999.90.5.0946 |
0.675 |
|
| 1999 |
Møller MB, Ino Y, Gerdes AM, Skjødt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia. 13: 453-9. PMID 10086736 |
0.513 |
|
| 1999 |
Louis DN, Zlatescu MC, Ino Y, Gregory J. LONG SURVIVALS AND THERAPEUTIC RESPONSES IN HIGH-GRADE GLIOMAS WITH CHROMOSOME 1p LOSS THAT ARE NOT CLASSIC ANAPLASTIC OLIGODENDROGLIOMAS Journal of Neuropathology and Experimental Neurology. 58: 512. DOI: 10.1097/00005072-199905000-00025 |
0.607 |
|
| 1998 |
Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF, Ramesh V, Louis DN. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. Journal of Neuropathology and Experimental Neurology. 57: 1164-7. PMID 9862639 DOI: 10.1097/00005072-199812000-00008 |
0.658 |
|
| 1998 |
Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute. 90: 1473-9. PMID 9776413 DOI: 10.1093/Jnci/90.19.1473 |
0.705 |
|
| Show low-probability matches. |